FDA record · warning letter

FDA warning letter: Peak Performance Peptides (Aug 24, 2026)

On Aug 24, 2026, FDA issued a warning letter to Peak Performance Peptides of Phoenix, AZ under the subject "Unapproved New Drugs/Misbranded". It names semaglutide, retatrutide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to Peak Performance Peptides
Field	What FDA’s record states	Source
Recipient	Peak Performance Peptides	FDA letter
Location	Phoenix, AZ	FDA letter
Letter date	Aug 24, 2026	FDA letter
Posted by FDA	Sep 1, 2026	FDA index
Issuing office	Center for Drug Evaluation and Research (CDER)	FDA letter
Subject	Unapproved New Drugs/Misbranded	FDA letter
MARCS-CMS number	735127	FDA letter
GLP-1 drugs named	Semaglutide, Retatrutide	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“Based on our review, “Bac water,” “GLP-3R” (retatrutide), “Semaglutide,” “SS-31,” “PT-141,” and “Tesamorelin” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).”FDA warning letter to Peak Performance Peptides, Aug 24, 2026 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters